Almirall's psoriasis drug drives 2021 growth ahead of duller 2022 outlook

Dermatology group Almirall’s 2021 growth was partially due to strong sales of psoriasis drug Ilumetri, which grew by 87 percent. With the recently announced European rollout of psoriasis cream Wynzora, developed by Danish MC2 Therapeutics, Almirall predicts a good start to 2022, although both growth and profits are expected to slow down.

Photo: Almirall / PR

On Monday, Spanish dermatology group Almirall has released its full-year report for 2021. The headliner has been sales of psoriasis drug Ilumetri, an anti-IL-23 monoclonal antibody treatments for adults that was launched around a year ago. Ilumetri sales reached EUR 82m in 2021, corresponding to a growth of 87 percent, according to the report.

Other takeaways include a good sales performances from Almirall’s acne treatment Seysara and Klisyri, a treatment for the dermatological disease known as actinic keratosis (AK), which was approved in the US in 2020 and in Europe in the second half of 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs